Tedisamil and dofetilide‐induced torsades de pointes, rate and potassium dependence
- 1 April 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 132 (7) , 1493-1500
Abstract
1. Tedisamil is a bradycardiac agent that prolongs the QT interval of the ECG and prevents cardiac arrhythmias. Given this profile, tedisamil might be expected to have proarrhythmic actions similar to Class III antiarrhythmic drugs. To address this question, the actions of dofetilide and tedisamil were examined in rabbit isolated hearts in which bradycardia was induced by AV ablation. 2. The QT interval was prolonged in a reverse rate-dependent fashion by dofetilide (3 and 30 nM) and tedisamil (0.3 and 3 microM). 3. Torsades de pointes was observed in 1/7 hearts treated with 3 nM dofetilide and 0/7 hearts treated with 0.3 microM tedisamil. The incidence of torsades de pointes was increased to 5/7 in hearts treated with 30 nM dofetilide and to 7/7 in hearts treated with 3 microM tedisamil (both P < 0.05 vs control). 4. The actions of 30 nM dofetilide and 3 microM tedisamil were also examined in hearts paced at 50, 100, 200 and 50 beats min(-1) successively. Both drugs caused torsades de pointes in 5/5 hearts paced at 50 beats min(-1); however, the incidence was reduced to 0/5 during pacing at 200 beats min(-1). Thus, drug-induced proarrhythmia was bradycardia-dependent. 5. Drug-induced prolongation of the interval between the peak and end of the T-wave (QTa-e) was reverse rate-dependent and was associated with the occurrence of torsades de pointes (r = 0.91, P < 0.01). 6. The results suggest that tedisamil, like dofetilide, presents a risk for development of torsades de pointes.Keywords
This publication has 35 references indexed in Scilit:
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- The M Cell:Journal of Cardiovascular Electrophysiology, 1999
- Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgeryInternational Journal of Cardiology, 1997
- [3H]Dofetilide Binding to Cardiac Myocytes: Modulation by Extracellular PotassiumJournal of Molecular and Cellular Cardiology, 1997
- Safety and Risk/Benefit Analysis of Ibutilide for Acute Conversion of Atrial Fibrillation/FlutterThe American Journal of Cardiology, 1996
- The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibersCardiovascular Research, 1996
- A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Study of Dofetilide in Patients with Inducible Sustained Ventricular TachyarrhythmiasJournal of Cardiovascular Electrophysiology, 1995
- Combined Administration of an Ik(ATP) Activator and Ito Blocker Increases Coronary Flow Independently of Effects on Heart Rate, QT Interval, and Ischaemia-Induced Ventricular Fibrillation in RatsJournal of Cardiovascular Pharmacology, 1993
- Influence of Tedisamil on the Initiation and Maintenance of Ventricular FibrillationJournal of Cardiovascular Pharmacology, 1991
- Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmiasThe American Journal of Cardiology, 1990